ArticleFrontiers in cellular and infection microbiology2021
Miltefosine Against
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Auranofin and iodoquinol as promising repurposing drugs against filamentous fungi: antifungal activity and cellular alterations.Microbiology spectrum · 2026Article
- Osh2 mediatesAntimicrobial agents and chemotherapy · 2025Article
- Article
- Article
- Milteforan, a promising veterinary commercial product against feline sporotrichosis.Microbiology spectrum · 2024Article
- Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.Clinical microbiology reviews · 2024Review
- Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs.Open forum infectious diseases · 2024Review
- Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.Infection and drug resistance · 2024Review
- Miltefosine: A Repurposing Drug against Mucorales Pathogens.Journal of fungi (Basel, Switzerland) · 2023Article
- Structural and Functional Alterations Caused by Aureobasidin A in Clinical Resistant Strains ofJournal of fungi (Basel, Switzerland) · 2023Article
- Potential Inhibitory Effect of Miltefosine against Terbinafine-ResistantPathogens (Basel, Switzerland) · 2023Article
- Promising Antifungal Molecules against Mucormycosis Agents Identified from Pandemic Response BoxJournal of fungi (Basel, Switzerland) · 2023Article
- Pandemic Response Box® library as a source of antifungal drugs against Scedosporium and Lomentospora species.PloS one · 2023Article
- In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins ResistantJournal of fungi (Basel, Switzerland) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.